July 2018
Volume 59, Issue 9
Open Access
ARVO Annual Meeting Abstract  |   July 2018
Functional and Anatomical Outcomes of Intravitreal Antiangiogenic Therapy for Choroidal Neovascularization Due to Causes Other Than AMD and Myopia
Author Affiliations & Notes
  • Roberto Gallego-Pinazo
    Ophthalmology, Oftalvist Clinic, Valencia, Spain
  • Ivo Gama
    Department of Ophthalmology, University Hospital Santa Maria, Northern Lisbon Hospital Center, Lisbon, Portugal
  • Paula Martínez López-Corell
    Institute for Health Research La Fe, Valencia, Spain
  • Rosa Dolz-Marco
    Institute for Health Research La Fe, Valencia, Spain
  • María Andreu-Fenoll
    Institute for Health Research La Fe, Valencia, Spain
  • Néstor García-Marín
    Institute for Health Research La Fe, Valencia, Spain
  • Footnotes
    Commercial Relationships   Roberto Gallego-Pinazo, Alcon (F), Allergan (F), Bayer (F), Heidelberg Engineergin (C), Heidelberg Engineergin (R), Novartis (C), Novartis (R), Novartis (F), Roche (C), Roche (R), Thea (F); Ivo Gama, None; Paula Martínez López-Corell, None; Rosa Dolz-Marco, Genentech (F), Heidelberg Engineergin (R), Novartis (R), Roche (R); María Andreu-Fenoll, None; Néstor García-Marín, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science July 2018, Vol.59, 3157. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Roberto Gallego-Pinazo, Ivo Gama, Paula Martínez López-Corell, Rosa Dolz-Marco, María Andreu-Fenoll, Néstor García-Marín; Functional and Anatomical Outcomes of Intravitreal Antiangiogenic Therapy for Choroidal Neovascularization Due to Causes Other Than AMD and Myopia
      . Invest. Ophthalmol. Vis. Sci. 2018;59(9):3157.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : To assess morphometric and functional changes in patients with vision loss due to CNV related to causes other than AMD and myopia

Methods : Retrospective review of patients with CNV not related to AMD or myopia managed with intravitreal antiangiogenic therapies between March 2011 and August 2016 at the Unit of Macula of the Hospital La Fe (Valencia, Spain). Information regarding best corrected visual acuity (BCVA), central retinal thickness (CRT), subfoveal choroidal thickness (SFCT), qualitative changes in the OCT scans (intraretinal fluid -IRF- and subretinal fluid -SRF-) and number of intravitreal injections was obtained from the medical records.

Results : Nineteen patients were included (mean age: 47.4 years; 68.4% female gender). The underlying diagnosis included multifocal choroiditis (n=6); birdshot chorioretinopathy (n=1); idiopathic macular telangiectasia type 2 (n=1); angioid streaks (n=3); adult onset foveomacular vitelliform dystrophy (n=2); and idiopathic CNV (n=5). The mean follow-up period was 32.4 months [13.0-44.3], with a mean number of intravitreal antiangiogenic drugs injections of 7.6 [1-21]. Mean BCVA improved from 0.37 +/- 0.3 logMAR to 0.15 +/-0.3 logMAR (p<0.001). CRT decrease correlated to BCVA improvement (r=0.83; p<0.001). IRF persisted in 57.9% of cases at the final follow-up visit, whereas SRF persisted in 36.9%. SFCT of eyes with CNV was significantly increased compared to the fellow eyes at baseline, and decreased through the follow-up.

Conclusions : Intravitreal injections of antiangiogenic drugs may achieve positive functional and anatomical outcomes in eyes with CNV related to causes other than AMD or myopia. SFCT was significantly increased at baseline compared to the fellow eyes.

This is an abstract that was submitted for the 2018 ARVO Annual Meeting, held in Honolulu, Hawaii, April 29 - May 3, 2018.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×